Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.8.0.1
Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Expenses        
Research and development $ 1,779,609 $ 1,086,107 $ 5,856,197 $ 2,939,746
General and administrative 1,155,038 698,125 2,911,538 2,586,050
Operating Expenses 2,934,647 1,784,232 8,767,735 5,525,796
Other loss (income)        
Change in fair value of stock option and derivative liabilities (2,160) 77,479 (57,839) (58,501)
Foreign exchange loss 6,420 6,897 57,406 13,726
Interest income (5,850) (148) (6,241) (249)
Other (income) loss (1,590) 84,228 (6,674) (45,024)
Net and comprehensive loss for the period 2,933,057 1,868,460 8,761,061 5,480,772
Computation of basic loss per share        
Net and comprehensive loss for the period 2,933,057 1,868,460 8,761,061 5,480,772
Series B Preferred stock dividend 46,626 209,811 142,358 676,865
Net and comprehensive loss available to common stockholders $ 2,979,683 $ 2,078,271 $ 8,903,419 $ 6,157,637
Basic and fully diluted loss per share $ 0.13 $ 0.18 $ 0.44 $ 0.54
Basic weighted average number of shares 22,832,445 11,574,052 20,179,765 11,432,376